SummaryRMgm-185
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18551171 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter (PubMed: PMID: 16242190). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | O. Silvie; K. Matuschewski |
Name Group/Department | Department of Parasitology |
Name Institute | Heidelberg University School of Medicine |
City | Heidelberg |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-185 |
Principal name | slarp(-)cl1; slarp(-)cl3 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of salivary gland sporozoites are formed. Infection of mice by mosquito bite or by inoculation of salivary gland sporozoites did not result in a blood stage infection. Sporozoites show normal hepatocyte traversal and invasion in vitro. |
Liver stage | Infection of rats and mice by mosquito bite or by inoculation of salivary gland sporozoites did not result in a blood stage infection. Sporozoites show normal hepatocyte traversal and invasion in vitro. The number of infected hepatocytes decreased over time in vitro. Mutant liver stages remained very small throughout the culture time, around 3–4 µm, which roughly corresponds to the size of 12–18h wild type parasites. Most mutant parasites were blocked at the one nucleus stage, even at late time points of infection. |
Additional remarks phenotype | Mutant/mutation Immunization of mice with the attenuated sporozoites of the mutant parasites induced only limited protective immune responses against challenge with wild type parasites. See also RMgm-185, a P. yoelii mutant lacking expression of SAP1/SLARP. Immunization with P. yoelii mutant sporozoites induces strong protective immunity. Using a mutant that expresses an mCherry tagged version of SAP1/SLARP (RMgm-186) a nuclear location/association of SLARP/SAP1 was observed. Based on these observations it has been suggested that SAP1/SLARP functions as a specific regulator of the expression of genes involved at early steps of liver stage development. Genbank accession no. EU579524. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0902100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1147000 | ||||||||||||||||||||||||
Gene product | sporozoite and liver stage asparagine-rich protein | sporozoite asparagine-rich protein | ||||||||||||||||||||||||
Gene product: Alternative name | SAP1, SLARP; sporozoite (and liver stage) asparagine-rich protein; S22 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | SacII/KpnI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | A small fragment of both the 5'-, and 3' coding sequence of SLARP remained in the genome after the disruption of the gene (159bp and 165bp respectively) | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |